• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Cancer Cells
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

Cancer: Chronic care vs. search for a cure

When the average person thinks of cancer research, one word is likely to spring to mind: cure. Almost everyone who has ever lost a friend or loved one to the disease is hoping for a permanent, reliable cure for cancer. The sooner, the better.

By
Ruth Williams, Ph.D.
Jan 21, 2014

William Sellers, M.D., Global Head of Oncology at the Novartis Institutes for BioMedical Research

So it may be surprising to learn there’s a disagreement within the research community about whether it is better to continue searching for a cure for cancer — a complex, multifaceted collection of diseases — or focus on chronic care treatments that prolong life and allow patients to better manage their disease. But the goal is clear for William Sellers, M.D., global head of Oncology at the Novartis Institutes for BioMedical Research in Cambridge, Mass.

“I have a fear that aiming for the chronic therapy is actually going to prevent us from getting to curative therapy,” he says. “If we had to settle for the chronic treatment of cancer, I would settle for that, but I think it would be a shame to aim for that.”

Sellers, who was driven to cancer research in part by the suffering he witnessed on cancer wards during his medical training, is adamant that he doesn’t want to just treat these lingering, lifestyle-destroying diseases. He wants to cure them—all of them. Indeed, striving for anything less does patients a disservice, he says.

“For the patient, the idea of living with cancer is a really tough thing to deal with,” Sellers says. “Certainly it’s better than dying of your cancer, but these patients are never certain about their future. They’re worried all the time about what might happen if the cancer comes back. That’s a pretty big toll,” he says.

The danger of defeatism

Treating cancer as a chronic condition is an idea that has emerged during the past few decades — “A period of, I would almost say, nihilism,” says Sellers. “People just sort of said, ‘We’re never going to cure cancer. Let’s forget trying to do that and let’s settle for managing it as a chronic disease.’ ”

I have a fear that aiming for the chronic therapy is actually going to prevent us from getting to curative therapy.

William Sellers, MD, Global Head of Oncology at Novartis Institutes for BioMedical Research

But there is reason to believe that chronic cancers and even the most life-threatening cancers, such as melanoma, glioma, and pancreatic cancer, could be cured. “Testicular cancer was far worse,” he says. “People lived six to eight weeks and that was it. It was one of the most aggressive, horrific cancers you can imagine. But now the standard therapy cures more than 90 percent of patients.”

The problem with settling for chronic treatments, according to Sellers, “is that if people only think we can treat cancer chronically they may not be willing to push the therapy to a point where cures might be obtainable. This is, I believe, a risk to the field.”

Despite the hopes of patients to be able to leave chemotherapy and its toxic side effects behind in favor of newer cancer medicines with fewer side effects, Sellers says researchers might have to be willing to allow some degree of toxicity in their treatments to enable cures. “If you are not willing to have any toxicity to the therapy, you may never achieve cures, even if you have the right drugs,” he says.

Individualized cancer care

Novartis researchers are looking deep within cancer cells, sequencing their genomes and developing therapies targeted to the specific mutations they may carry.

Lung cancer, for example, comprises several different diseases with distinct genetic roots. In a subgroup of patients with lung cancer, tumor growth is driven by mutations in a gene called EGFR. These patients benefit dramatically from drugs that target EGFR. Mutations in the same gene cause some cases of colon cancer and glioblastoma. In other words, the same molecular pathway plays a role in other types of cancer. If doctors know the genetic profile of a tumor, then they can select the appropriate targeted therapy, assuming that it already exists.

Sellers is also excited about the potential of a treatment developed by Carl June, a professor of immunotherapy at the University of Pennsylvania, and his colleagues. The new technique involves extracting a patient’s immune cells, genetically reprogramming them to recognize and kill cancer cells and then returning them to the patient.

“Carl showed that the reprogrammed T cells expand dramatically and wipe out the tumor,” he says. “In a significant number of cases, patients now appear to be cancer-free.”

Engineering T cells is not the only way Novartis researchers are using aspects of the immune system to target and kill cancer cells. In another approach, they are planning to attach toxins to antibodies that have been specifically designed to recognize cancer cells.

“Normally such an agent would be too toxic to give to a human because it would be nonspecific and it would kill healthy and tumor cells,” Sellers says.

When it’s attached to an antibody, however, it homes to the cancer cells, killing only them. Such antibody-drug conjugates represent another weapon in the oncology arsenal.

“Ultimately, we’re going to have genetic information from every patient’s tumor, we’re going to have some idea of the surface expression of the patient’s tumor, and we’re going to have combinations of genetic and immunological therapies,” he says. Chemotherapy and radiation may continue to be effective in the context of these newer therapies.

Armed with these options, new and old, Sellers is confident that “one tumor at a time, we’ll get to curative states, with patients coming off therapy and living tumor free.”

Tags: 
Cancer, Chronic Illness, Gene Sequencing

Ruth Williams, Ph.D.

Ruth Williams, Ph.D.

is a science writer whose work has appeared in Nature, The Scientist and The Lancet, among others.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.